胰高血糖素样肽1类药物在2型糖尿病治疗中的应用  

Application of GLP-1 Drugs in the Treatment of Type 2 Diabetes

作　　者：马淑芳[1] 王运兴[1] 孙丽静[1] 

机构地区：[1]河北省唐县人民医院内分泌科,河北保定072350

出　　处：《医学综述》2014年第16期2978-2980,共3页Medical Recapitulate

基　　金：河北省卫生厅青年科技项目(20100547)

摘　　要：2型糖尿病(T2DM)的治疗目标是良好控制血糖,同时尽最大努力减少其相关的大血管和微血管并发症。新近出现的胰高血糖素样肽1(GLP-1)类药物主要有两大类,即GLP-1类似物和二肽基肽酶4(DPP-4)抑制剂。作为新型降糖药,此类药物集多效于一身,不仅保留了GLP-1的降糖、β细胞保护等多种生理作用,而且具备低血糖风险低,安全性好等特点,还能全面干预减轻体质量、降血压、调血脂等,较胰岛素、双胍类、磺酰脲类等常规治疗药物有明显优势。For type 2 diabetes mellitus（T2DM） ,the main goal of treatment is a good control of blood glucose, and make the greatest efforts to reduce its associated vascular and microvascular complications. The newly emerging glueagon-like peptide-1 （ GLP-1 ） drugs, are generally divided into two major categories, named GLP-1 analogs and dipeptidyl peptidase-4 （ DPP-4 ） inhibitors. As a new type of antidiabetic drugs, these drugs are featured with multi-effect-in-one, not only retaining a variety of physiological effects of GLP-1 hypoglycemic, beta cell protection with a low risk of hypoglycemia and good safety, but also comprehensively intervening the weight loss, blood pressure,lipid and other cardiovascular risk factors, which has obvious ad- vantages over insulin, mefforrnin, sulfonylurea and other conventional treatment.

关 键 词：胰高血糖素样肽1 胰高血糖素样肽1类似物 二肽基肽酶4抑制剂 2型糖尿病 

分 类 号：R587.1[医药卫生—内分泌]